Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method

Overview of attention for article published in Biologics: Targets & Therapy, April 2014

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 53 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 22 publications that cite this research output.

22

The most recent citing publications are shown below. View all 22 publications that cite this research output on Dimensions.

Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors

Article in Advances in Therapy (April 2024)

Cost‐effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate–severe to severe hemophilia B in China

Article in Pediatric Blood & Cancer (February 2023)

Treatment satisfaction and limitations in haemophilia A, with a focus on factor VIII product storage conditions: patients’ perspectives and challenges

Article in Drugs & Therapy Perspectives (December 2022)